Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Bruce A. Chabner, M.D.

TitleProfessor of Medicine
InstitutionMassachusetts General Hospital
DepartmentMedicine
AddressMassachusetts General Hospital
Hematology/Oncology
100 Blossom Street
Boston MA 02114
Phone617/724-3200
Fax617/724-3166

 Mentoring 
 current student opportunities
Cancer Drug Development[login at prompt]
Available: 07/01/12, Expires: 07/01/13

Examine the impact of patient selection, based on molecular profiling of patient's tumor, on the success of new drug development in cancer. The ability to select patients for early clinical trials, based on molecularly profiling tumors, has greatly expedited drug evaluation in recent studies at the Harvard Hospitals. The impact of this change in strategy on the time to approval of cancer drugs will be the subject of this study.


 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Cote GM, Sawyer DB, Chabner BA. ERBB2 inhibition and heart failure. N Engl J Med. 2013 Feb 28; 368(9):876.
    View in: PubMed
  2. Cote GM, Sawyer DB, Chabner BA. ERBB2 inhibition and heart failure. N Engl J Med. 2012 Nov 29; 367(22):2150-3.
    View in: PubMed
  3. Chabner BA. That old devil moon. Oncologist. 2012; 17(11):1349-50.
    View in: PubMed
  4. Raj A, Ko N, Battaglia TA, Chabner BA, Moy B. Patient navigation for underserved patients diagnosed with breast cancer. Oncologist. 2012; 17(8):1027-31.
    View in: PubMed
  5. Chabner BA, Smith M. Call it cancer. Oncologist. 2012; 17(2):149-50.
    View in: PubMed
  6. Fojo T, Bates S, Chabner BA. Editor's Note ...Clinical Trial Reports: A New Section. Oncologist. 2012; 17(1):11-2.
    View in: PubMed
  7. Chabner BA. Drug shortages--a critical challenge for the generic-drug market. N Engl J Med. 2011 Dec 8; 365(23):2147-9.
    View in: PubMed
  8. Wen PY, Schiff D, Cloughesy TF, Reardon DA, Batchelor TT, Chabner BA, Flaherty K, de Groot JF, Gilbert MR, Galanis E, Chang SM, Schwartz GK, Peereboom D, Mehta MP, Yung WK, Grossman SA, Prados MD, DeAngelis LM. It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol. 2011 Aug 20; 29(24):3211-3.
    View in: PubMed
  9. Fathi AT, Chabner BA. FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations. Oncologist. 2011; 16(8):1162-74.
    View in: PubMed
  10. La Vecchia C, Giordano SH, Hortobagyi GN, Chabner B. Overweight, obesity, diabetes, and risk of breast cancer: interlocking pieces of the puzzle. Oncologist. 2011; 16(6):726-9.
    View in: PubMed
  11. Chabner BA. Early accelerated approval for highly targeted cancer drugs. N Engl J Med. 2011 Mar 24; 364(12):1087-9.
    View in: PubMed
  12. Chabner BA. The oncologist Chinese edition: a global mission, a unifying bond. Oncologist. 2011; 16(6):I.
    View in: PubMed
  13. Chabner BA. Self-plagiarism. Oncologist. 2011; 16(10):1347-8.
    View in: PubMed
  14. Moy B, Chabner BA. Patient navigator programs, cancer disparities, and the patient protection and affordable care act. Oncologist. 2011; 16(7):926-9.
    View in: PubMed
  15. Murphy JP, Chabner BA. Reflections on the knife edge. Oncologist. 2011; 16(2):257-9.
    View in: PubMed
  16. Chabner BA. New results will change the paradigm for phase I trials and drug approval. Oncologist. 2010; 15(10):1023-5.
    View in: PubMed
  17. Donelan K, Mailhot JR, Dutwin D, Barnicle K, Oo SA, Hobrecker K, Percac-Lima S, Chabner BA. Patient perspectives of clinical care and patient navigation in follow-up of abnormal mammography. J Gen Intern Med. 2011 Feb; 26(2):116-22.
    View in: PubMed
  18. Chabner BA. Academia-pharma intersect: providing a broader perspective on drug development synergies between academia and industry. Oncologist. 2010; 15(1):1-2.
    View in: PubMed
  19. Zhu AX, Chabner BA, Tanabe KK. New trends and novel treatment for hepatocellular carcinoma: a global perspective. Oncologist. 2010; 15 Suppl 4:1-4.
    View in: PubMed
  20. Chabner BA. About Eli. Oncologist. 2010; 15(4):329-31.
    View in: PubMed
  21. Chong CR, Chabner BA. Mysterious metformin. Oncologist. 2009 Dec; 14(12):1178-81.
    View in: PubMed
  22. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009 Nov 10; 27(32):5459-68.
    View in: PubMed
  23. Donelan K, Hobrecker K, Schapira L, Mailhot JR, Goulart BH, Chabner BA. Medical interpreter knowledge of cancer and cancer clinical trials. Cancer. 2009 Jul 15; 115(14):3283-92.
    View in: PubMed
  24. Chabner BA. Obituary. Cancer Sci. 2009 Apr; 100(4):565-6.
    View in: PubMed
  25. Chabner BA. Ghost writers in the sky. Oncologist. 2009 Mar; 14(3):199-200.
    View in: PubMed
  26. Chabner BA. The National Cancer Institute and its Director: worthy of our full support. Oncologist. 2009 Feb; 14(2):108-9.
    View in: PubMed
  27. Raje N, Hideshima T, Mukherjee S, Raab M, Vallet S, Chhetri S, Cirstea D, Pozzi S, Mitsiades C, Rooney M, Kiziltepe T, Podar K, Okawa Y, Ikeda H, Carrasco R, Richardson PG, Chauhan D, Munshi NC, Sharma S, Parikh H, Chabner B, Scadden D, Anderson KC. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia. 2009 May; 23(5):961-70.
    View in: PubMed
  28. Schapira L, Gordon-Rowe L, Martignetti R, Washington D, Bartholomay M, Greenberg D, Lathan C, LaFrancesca J, Lynch T, Chabner B. Racism in the chemotherapy infusion unit: a nurse's story. Oncologist. 2008 Nov; 13(11):1177-80.
    View in: PubMed
  29. Chabner BA. Dr. Joseph R. Bertino: a reflection. Oncologist. 2008 Oct; 13(10):1034-5.
    View in: PubMed
  30. Curt GA, Chabner BA. One in five cancer clinical trials is published: a terrible symptom--what's the diagnosis? Oncologist. 2008 Sep; 13(9):923-4.
    View in: PubMed
  31. Chabner BA. Preserving the sacred bond: an audit must be performed. Oncologist. 2008 Sep; 13(9):922.
    View in: PubMed
  32. Schapira L, Vargas E, Hidalgo R, Brier M, Sanchez L, Hobrecker K, Lynch T, Chabner B. Lost in translation: integrating medical interpreters into the multidisciplinary team. Oncologist. 2008 May; 13(5):586-92.
    View in: PubMed
  33. Chabner BA. Smoke, then fire: lung cancer screening studies under further scrutiny. Oncologist. 2008 Apr; 13(4):348-9.
    View in: PubMed
  34. Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, Raffeld M, Gutierrez M, Chabner BA, Staudt L, Jaffe ES, Janik JE. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008 Jun 1; 26(16):2717-24.
    View in: PubMed
  35. Ajijola OA, Nandigam KV, Chabner BA, Orencole M, Dec GW, Ruskin JN, Singh JP. Usefulness of cardiac resynchronization therapy in the management of Doxorubicin-induced cardiomyopathy. Am J Cardiol. 2008 May 1; 101(9):1371-2.
    View in: PubMed
  36. Chabner BA. Conflict of interest: in the eye of the beholder? Oncologist. 2008 Mar; 13(3):212-3.
    View in: PubMed
  37. Novina CD, Chabner BA. RNA-Directed Therapy: The Next Step in the miRNA Revolution. Oncologist. 2008 Jan; 13(1):1-3.
    View in: PubMed
  38. Chabner B. Advances and challenges in the use of biomarkers in clinical trials. Clin Adv Hematol Oncol. 2008 Jan; 6(1):42-3.
    View in: PubMed
  39. Goulart BH, Clark JW, Pien HH, Roberts TG, Finkelstein SN, Chabner BA. Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6719-26.
    View in: PubMed
  40. Chabner BA, Ratain MJ. Clarification regarding "phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties" and the accompanying commentary, "phase II cancer trials: out of control?". Clin Cancer Res. 2007 Nov 1; 13(21):6540.
    View in: PubMed
  41. Kwak EL, Clark JW, Chabner B. Targeted agents: the rules of combination. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5232-7.
    View in: PubMed
  42. Chabner BA. Orange alert for oncologists. Oncologist. 2007 Aug; 12(8):902-3.
    View in: PubMed
  43. Chabner B. Phase II cancer trials: out of control? Clin Cancer Res. 2007 Apr 15; 13(8):2307-8.
    View in: PubMed
  44. Chabner BA, Roberts TG. The FDA in 2006: reasons for optimism. Oncologist. 2007 Mar; 12(3):247-9.
    View in: PubMed
  45. Chabner BA, Roberts TG. Setting fair prices for life-saving drugs. Virtual Mentor. 2007; 9(1):38-43.
    View in: PubMed
  46. Chabner BA. Editors and authors: a sacred trust. Oncologist. 2006 Oct; 11(9):959.
    View in: PubMed
  47. Penson RT, Kyriakou H, Zuckerman D, Chabner BA, Lynch TJ. Teams: communication in multidisciplinary care. Oncologist. 2006 May; 11(5):520-6.
    View in: PubMed
  48. Abel GA, Penson RT, Joffe S, Schapira L, Chabner BA, Lynch TJ. Direct-to-consumer advertising in oncology. Oncologist. 2006 Feb; 11(2):217-26.
    View in: PubMed
  49. Penson RT, Partridge RA, Rudd P, Seiden MV, Nelson JE, Chabner BA, Lynch TJ. Laughter: the best medicine? Oncologist. 2005 Sep; 10(8):651-60.
    View in: PubMed
  50. Chabner BA, Murphy MJ. Breast cancer: a tale of two centuries: with implications for understanding cancer metastasis and cancer stem cell biology. Oncologist. 2005 Jun-Jul; 10(6):369.
    View in: PubMed
  51. Wolpin BM, Chabner BA, Lynch TJ, Penson RT. Learning to cope: how far is too close? Oncologist. 2005 Jun-Jul; 10(6):449-56.
    View in: PubMed
  52. Penson RT, Partridge RA, Shah MA, Giansiracusa D, Chabner BA, Lynch TJ. Fear of death. Oncologist. 2005 Feb; 10(2):160-9.
    View in: PubMed
  53. Chabner BA, Roberts TG. Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer. 2005 Jan; 5(1):65-72.
    View in: PubMed
  54. Roberts TG, Goulart BH, Squitieri L, Stallings SC, Halpern EF, Chabner BA, Gazelle GS, Finkelstein SN, Clark JW. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA. 2004 Nov 3; 292(17):2130-40.
    View in: PubMed
  55. Roberts TG, Chabner BA. Beyond fast track for drug approvals. N Engl J Med. 2004 Jul 29; 351(5):501-5.
    View in: PubMed
  56. Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, Parkinson DR, Peck J, Ruddon RW, Sigman CC, Slamon DJ. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res. 2004 Jun 1; 10(11):3885-96.
    View in: PubMed
  57. Kelloff GJ, Coffey DS, Chabner BA, Dicker AP, Guyton KZ, Nisen PD, Soule HR, D'Amico AV. Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer. Clin Cancer Res. 2004 Jun 1; 10(11):3927-33.
    View in: PubMed
  58. Zhu AX, Puchalski TA, Stanton VP, Ryan DP, Clark JW, Nesbitt S, Charlat O, Kelly P, Kreconus E, Chabner BA, Supko JG. Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer. Clin Colorectal Cancer. 2004 Feb; 3(4):225-34.
    View in: PubMed
  59. Parles K, Chabner B. "The patient failed chemotherapy" ...an expunged phrase. Oncologist. 2004; 9(6):719; author reply 719.
    View in: PubMed
  60. Chabner BA. The miracle of Iressa. Oncologist. 2004; 9(3):245-6.
    View in: PubMed
  61. Chabner BA. CME: the "third phase" of a doctor's education. Oncologist. 2004; 9(3):241.
    View in: PubMed
  62. Penson RT, Schapira L, Daniels KJ, Chabner BA, Lynch TJ. Cancer as metaphor. Oncologist. 2004; 9(6):708-16.
    View in: PubMed
  63. Penson RT, Talsania SH, Chabner BA, Lynch TJ. Help me help you: support groups in cancer therapy. Oncologist. 2004; 9(2):217-25.
    View in: PubMed
  64. Roberts TG, Lynch TJ, Chabner BA. The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision. J Clin Oncol. 2003 Oct 1; 21(19):3683-95.
    View in: PubMed
  65. Brugarolas J, Clark JW, Chabner B. Using "rationally designed drugs" rationally. Lancet. 2003 May 24; 361(9371):1758-9.
    View in: PubMed
  66. Chabner BA. Cancer therapy and survivorship. Cancer Epidemiol Biomarkers Prev. 2003 Mar; 12(3):269s.
    View in: PubMed
  67. Dias L, Chabner BA, Lynch TJ, Penson RT. Breaking bad news: a patient's perspective. Oncologist. 2003; 8(6):587-96.
    View in: PubMed
  68. Knuti KA, Wharton RH, Wharton KL, Chabner BA, Lynch TJ, Penson RT. Living as a cancer surpriser: a doctor tells his story. Oncologist. 2003; 8(1):108-22.
    View in: PubMed
  69. Penson RT, Fergus LA, Haston RJ, Clark JR, Demotses A, O'Connell JJ, Chabner BA, Lynch TJ. The Kenneth B. Schwartz Center at Massachusetts General Hospital hematology-oncology department: hope for the homeless. Oncologist. 2003; 8(5):488-95.
    View in: PubMed
  70. Chabner BA. The dilemma of drug development and approval. Oncologist. 2003; 8(6):500.
    View in: PubMed
  71. Chabner BA. A tribute to Paul Calabresi: the man and the Matterhorn. Oncologist. 2003; 8(6):602-3.
    View in: PubMed
  72. Penson RT, Nunn C, Younger J, Schaeffer NJ, Chabner BA, Fricchione GL, Quinn TE, Lynch TJ. Trust violated: analgesics for addicts. Oncologist. 2003; 8(2):199-209.
    View in: PubMed
  73. Garraway LA, Chabner B. MDR1 inhibition: less resistance or less relevance? Eur J Cancer. 2002 Dec; 38(18):2337-40.
    View in: PubMed
  74. Tashjian AH, Chabner BA. Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res. 2002 Jul; 17(7):1151-61.
    View in: PubMed
  75. Mujagic H, Chabner BA, Mujagic Z. Mechanisms of action and potential therapeutic uses of thalidomide. Croat Med J. 2002 Jun; 43(3):274-85.
    View in: PubMed
  76. Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, Steinberg SM, Little RF, Janik J, Gutierrez M, Raffeld M, Staudt L, Cheson BD, Longo DL, Harris N, Jaffe ES, Chabner BA, Wittes R, Balis F. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002 Apr 15; 99(8):2685-93.
    View in: PubMed
  77. Wilson WH, Gutierrez M, O'Connor P, Frankel S, Jaffe E, Chabner BA, Grossbard ML. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. Semin Oncol. 2002 Feb; 29(1 Suppl 2):41-7.
    View in: PubMed
  78. Penson RT, Rauch PK, McAfee SL, Cashavelly BJ, Clair-Hayes K, Dahlin C, Green KM, Chabner BA, Lynch TJ. Between parent and child: negotiating cancer treatment in adolescents. Oncologist. 2002; 7(2):154-62.
    View in: PubMed
  79. Penson RT, Benson RC, Parles K, Chabner BA, Lynch TJ. Virtual connections: Internet health care. Oncologist. 2002; 7(6):555-68.
    View in: PubMed
  80. Chabner BA. The trust factor. Oncologist. 2002; 7(2):94-5.
    View in: PubMed
  81. Chabner BA, Kaufman D. Pity the poor consumer. Oncologist. 2002; 7(6):475-6.
    View in: PubMed
  82. Penson RT, Green KM, Chabner BA, Lynch TJ. When does the responsibility of our care end: bereavement. Oncologist. 2002; 7(3):251-8.
    View in: PubMed
  83. Knuti KA, Amrein PC, Chabner BA, Lynch TJ, Penson RT. Faith, identity, and leukemia: when blood products are not an option. Oncologist. 2002; 7(4):371-80.
    View in: PubMed
  84. Chabner BA. Cytotoxic agents in the era of molecular targets and genomics. Oncologist. 2002; 7 Suppl 3:34-41.
    View in: PubMed
  85. Roberts TG, Lynch TJ, Chabner BA. Choosing chemotherapy for lung cancer based on cost: not yet. Oncologist. 2002; 7(3):177-8.
    View in: PubMed
  86. Penson RT, Castro CM, Seiden MV, Chabner BA, Lynch TJ. Complementary, alternative, integrative, or unconventional medicine? Oncologist. 2001; 6(5):463-73.
    View in: PubMed
  87. Penson RT, Svendsen SS, Chabner BA, Lynch TJ, Levinson W. Medical mistakes: a workshop on personal perspectives. Oncologist. 2001; 6(1):92-9.
    View in: PubMed
  88. Penson RT, Seiden MV, Chabner BA, Lynch TJ. Caring for colleagues. Oncologist. 2001; 6(2):197-204.
    View in: PubMed
  89. Chabner BA. The oncologic four-minute mile. Oncologist. 2001; 6(3):230-2.
    View in: PubMed
  90. Penson RT, Yusuf RZ, Chabner BA, Lafrancesca JP, McElhinny M, Axelrad AS, Lynch TJ. Losing God. Oncologist. 2001; 6(3):286-97.
    View in: PubMed
  91. Ryan PD, Chabner BA. On receptor inhibitors and chemotherapy. Clin Cancer Res. 2000 Dec; 6(12):4607-9.
    View in: PubMed
  92. Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, Fojo A, Wilson WH. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol. 2000 Nov 1; 18(21):3633-42.
    View in: PubMed
  93. Penson RT, Seiden MV, Shannon KM, Lubratovich ML, Roche M, Chabner BA, Lynch TJ. Communicating genetic risk: pros, cons, and counsel. Oncologist. 2000; 5(2):152-61.
    View in: PubMed
  94. Krakauer EL, Penson RT, Truog RD, King LA, Chabner BA, Lynch TJ. Sedation for intractable distress of a dying patient: acute palliative care and the principle of double effect. Oncologist. 2000; 5(1):53-62.
    View in: PubMed
  95. Chabner BA. About sorrow Oncologist. 2000; 5(5):XVI.
    View in: PubMed
  96. Penson RT, Gallagher J, Gioiella ME, Wallace M, Borden K, Duska LA, Talcott JA, McGovern FJ, Appleman LJ, Chabner BA, Lynch TJ. Sexuality and cancer: conversation comfort zone. Oncologist. 2000; 5(4):336-44.
    View in: PubMed
  97. Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res. 1999 Nov; 5(11):3445-53.
    View in: PubMed
  98. Chabner BA. Promising New Drugs and Combinations. Fulfilling Our Pledge. Oncologist. 1999; 4(4):VIII.
    View in: PubMed
  99. Grem JL, Takimoto CH, Multani P, Chu E, Ryan D, Chabner BA, Allegra CJ, Johnston PG. Antimetabolites. Cancer Chemother Biol Response Modif. 1999; 18:1-38.
    View in: PubMed
  100. O'Shea EM, Lintz KC, Penson RT, Seiden MV, Chabner BA, Lynch TJ. A staff dialogue on caring for a cancer patient who commits suicide: psychosocial issues faced by patients, their families, and caregivers. Oncologist. 1999; 4(2):122-7.
    View in: PubMed
  101. Goodman A, Penson RT, Blatman R, McIntyre J, Gioiella ME, Chabner BA, Lynch TJ. A staff dialogue on a socially distanced patient: psychosocial issues faced by patients, their families, and caregivers. Oncologist. 1999; 4(5):417-24.
    View in: PubMed
  102. Chabner BA. Anatomy of a joint venture: Dana Farber/Partners Cancer Care. Trans Am Clin Climatol Assoc. 1999; 110:168-79; discussion 179-80.
    View in: PubMed
  103. O'Shea EM, Penson RT, Stern TA, Younger J, Chabner BA, Lynch TJ. A staff dialogue on do not resuscitate orders: psychosocial issues faced by patients, their families, and caregivers. Oncologist. 1999; 4(3):256-62.
    View in: PubMed
  104. Lintz KC, Penson RT, Cassem N, Harmon DC, Chabner BA, Lynch TJ. A staff dialogue on aggressive palliative treatment demanded by a terminally ill patient: psychosocial issues faced by patients, their families, and caregivers. Oncologist. 1999; 4(1):70-6.
    View in: PubMed
  105. Ryan DP, Penson RT, Ahmed S, Chabner BA, Lynch TJ. Reality testing in cancer treatment: the phase I trial of endostatin. Oncologist. 1999; 4(6):501-8.
    View in: PubMed
  106. Chabner BA, Boral AL, Multani P. Translational research: walking the bridge between idea and cure--seventeenth Bruce F. Cain Memorial Award lecture. Cancer Res. 1998 Oct 1; 58(19):4211-6.
    View in: PubMed
  107. Lintz KC, Penson RT, Chabner BA, Mack S, Lynch TJ. Schwartz Center Rounds. A Staff Dialogue on Phase I Trials: Psychosocial Issues Faced by Patients, Their Families, and Caregivers. Oncologist. 1998; 3(5):357-364.
    View in: PubMed
  108. Chabner BA, Friedberg J. ASCO 1998: A Commentary. Oncologist. 1998; 3(4):263-266.
    View in: PubMed
  109. Boral AL, Dessain S, Chabner BA. Clinical evaluation of biologically targeted drugs: obstacles and opportunities. Cancer Chemother Pharmacol. 1998; 42 Suppl:S3-21.
    View in: PubMed
  110. Lintz KC, Penson RT, Chabner BA, Lynch TJ. Schwartz Center Rounds. A Staff Dialogue on Caring for an Intensely Spiritual Patient: Psychosocial Issues Faced By Patients, Their Families, and Caregivers. Oncologist. 1998; 3(6):439-445.
    View in: PubMed
  111. Suit H, Isselbacher K, Chabner B. Winning the war on cancer. N Engl J Med. 1997 Sep 25; 337(13):936-7; author reply 937-8.
    View in: PubMed
  112. Chabner BA, Haluska FG, Talcott JA. Screening strategies for cancer. Implications and results. JAMA. 1997 May 14; 277(18):1475-6.
    View in: PubMed
  113. Johnston PG, Takimoto CH, Grem JL, Fidias P, Grossbard ML, Chabner BA, Allegra CJ, Chu E. Antimetabolites. Cancer Chemother Biol Response Modif. 1997; 17:1-39.
    View in: PubMed
  114. Chabner BA. Cancer: A Personal Journey. Notes from the Edge.The Diary of Peter J. Morgan, M.D. Oncologist. 1997; 2(4):206-207.
    View in: PubMed
  115. Treon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. Clin Chem. 1996 Aug; 42(8 Pt 2):1322-9.
    View in: PubMed
  116. Chabner BA. Back to the Future for Clinical Oncology. Oncologist. 1996; 1(1 & 2):I.
    View in: PubMed
  117. Bates SE, Wilson WH, Fojo AT, Alvarez M, Zhan Z, Regis J, Robey R, Hose C, Monks A, Kang YK, Chabner B. Clinical Reversal of Multidrug Resistance. Oncologist. 1996; 1(4):269-275.
    View in: PubMed
  118. Fidias P, Chabner BA, Grossbard ML. Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders. Oncologist. 1996; 1(3):125-139.
    View in: PubMed
  119. Bates SE, Wilson WH, Fojo AT, Alvarez M, Zhan Z, Regis J, Robey R, Hose C, Monks A, Kang YK, Chabner B. Clinical reversal of multidrug resistance. Stem Cells. 1996 Jan; 14(1):56-63.
    View in: PubMed
  120. Johnston PG, Takimoto CH, Grem JL, Chabner BA, Allegra CJ, Chu E. Antimetabolites. Cancer Chemother Biol Response Modif. 1996; 16:1-27.
    View in: PubMed
  121. Pinedo HM, Longo DL, Chabner BA. Cancer chemotherapy and biological response modifiers annual 16. Introduction. Cancer Chemother Biol Response Modif. 1996; 16:xvii-xviii.
    View in: PubMed
  122. Clarkson B, Chabner BA, Weinberg RA. Targets for specific therapies in leukemia. Cancer Res. 1995 Oct 1; 55(19):4488-98.
    View in: PubMed
  123. Clark JW, Chabner BA. Suramin and prostate cancer: where do we go from here? J Clin Oncol. 1995 Sep; 13(9):2155-7.
    View in: PubMed
  124. Wilson WH, Jamis-Dow C, Bryant G, Balis FM, Klecker RW, Bates SE, Chabner BA, Steinberg SM, Kohler DR, Wittes RE. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J Clin Oncol. 1995 Aug; 13(8):1985-94.
    View in: PubMed
  125. Wilson WH, Chabner BA, Bryant G, Bates S, Fojo A, Regis J, Jaffe ES, Steinberg SM, Goldspiel BR, Cheson BD, et al. Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. J Clin Oncol. 1995 Feb; 13(2):381-6.
    View in: PubMed
  126. Bates SE, Fojo AT, Weinstein JN, Myers TG, Alvarez M, Pauli KD, Chabner BA. Molecular targets in the National Cancer Institute drug screen. J Cancer Res Clin Oncol. 1995; 121(9-10):495-500.
    View in: PubMed
  127. Wilson WH, Bates SE, Fojo A, Chabner BA. Modulation of multidrug resistance by dexverapamil in EPOCH-refractory lymphomas. J Cancer Res Clin Oncol. 1995; 121 Suppl 3:R25-9.
    View in: PubMed
  128. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA, Allegra CJ. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol. 1994 Dec; 12(12):2640-7.
    View in: PubMed
  129. Chabner BA. National Surgical Adjuvant Breast and Bowel Project publications in Cancer 1980-1993. Cancer. 1994 Jul 15; 74(2):780-1.
    View in: PubMed
  130. Balch CM, Bland KI, Brennan MF, Cameron JL, Chabner BA, Copeland EM, Hoskins WJ, Karakousis CP, Niederhuber JE, Pollock RE, et al. What is a surgical oncologist? Ann Surg Oncol. 1994 Jan; 1(1):2-4.
    View in: PubMed
  131. Chabner BA, Bates SE, Fojo AT, Spolyar M, Wilson WH. Drug resistance in adult lymphomas. Semin Hematol. 1994 Jan; 31(1):70-87.
    View in: PubMed
  132. Chabner BA, Chabner ES. Mitotic inhibitors. Cancer Chemother Biol Response Modif. 1994; 15:58-66.
    View in: PubMed
  133. Chu E, Johnston PG, Grem JL, Takimoto CH, Van Groeningen C, Chabner BA, Allegra CJ. Antimetabolites. Cancer Chemother Biol Response Modif. 1994; 15:1-31.
    View in: PubMed
  134. Chabner BA. Multidrug resistance: mechanism and therapy. Jpn J Cancer Res. 1993 Dec; 84(12):inside front cover.
    View in: PubMed
  135. Goldspiel BR, Kohler DR, Koustenis AG, Wilson WH, Tolcher AW, O'Shaughnessy JA, Wittes RE, Chabner BA. Paclitaxel administration using portable infusion pumps. J Clin Oncol. 1993 Nov; 11(11):2287-8.
    View in: PubMed
  136. Chabner BA, Levy R. Funding for gene therapy. Science. 1993 May 14; 260(5110):877-8.
    View in: PubMed
  137. Chabner BA. Biological basis for cancer treatment. Ann Intern Med. 1993 Apr 15; 118(8):633-7.
    View in: PubMed
  138. Saikawa Y, Knight CB, Saikawa T, Page ST, Chabner BA, Elwood PC. Decreased expression of the human folate receptor mediates transport-defective methotrexate resistance in KB cells. J Biol Chem. 1993 Mar 5; 268(7):5293-301.
    View in: PubMed
  139. Friedman MA, Chabner BA, Trimble EL, Adams J, Arbuck SG. Unrealistic expectations in the diagnosis and treatment of ovarian cancer. N Engl J Med. 1993 Mar 4; 328(9):664; author reply 664-5.
    View in: PubMed
  140. Bicher A, Sarosy G, Kohn E, Adamo DO, Davis P, Jacob J, Chabner BA, Reed E. Age does not influence taxol dose intensity in recurrent carcinoma of the ovary. Cancer. 1993 Jan 15; 71(2 Suppl):594-600.
    View in: PubMed
  141. Chu E, Johnston PG, Takimoto CH, Politi PM, Grem JL, Chabner BA, Allegra CJ. Antimetabolites. Cancer Chemother Biol Response Modif. 1993; 14:1-25.
    View in: PubMed
  142. Chabner BA. Antimitotic drugs. Cancer Chemother Biol Response Modif. 1993; 14:55-60.
    View in: PubMed
  143. Grever MR, Schepartz SA, Chabner BA. The National Cancer Institute: cancer drug discovery and development program. Semin Oncol. 1992 Dec; 19(6):622-38.
    View in: PubMed
  144. Urba WJ, Wilson WH, Duffey PL, Wittes R, Chabner BA, Longo DL. Recent National Cancer Institute lymphoma trials of etoposide-containing combination chemotherapy. Semin Oncol. 1992 Dec; 19(6 Suppl 13):26-32.
    View in: PubMed
  145. Chabner BA, Friedman MA. Progress against rare and not-so-rare cancers. N Engl J Med. 1992 Feb 20; 326(8):563-5.
    View in: PubMed
  146. Chabner BA. Mitotic inhibitors. Cancer Chemother Biol Response Modif. 1992; 13:69-74.
    View in: PubMed
  147. Chabner BA. Camptothecins. J Clin Oncol. 1992 Jan; 10(1):3-4.
    View in: PubMed
  148. Chu E, Grem JL, Johnston PG, Politi PM, Chabner BA, Allegra CJ. Antimetabolites. Cancer Chemother Biol Response Modif. 1992; 13:1-30.
    View in: PubMed
  149. Johnston PG, Liang CM, Henry S, Chabner BA, Allegra CJ. Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. Cancer Res. 1991 Dec 15; 51(24):6668-76.
    View in: PubMed
  150. O'Shaughnessy JA, Wittes RE, Burke G, Friedman MA, Johnson JR, Niederhuber JE, Rothenberg ML, Woodcock J, Chabner BA, Temple R. Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials. J Clin Oncol. 1991 Dec; 9(12):2225-32.
    View in: PubMed
  151. Chu E, Koeller DM, Casey JL, Drake JC, Chabner BA, Elwood PC, Zinn S, Allegra CJ. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci U S A. 1991 Oct 15; 88(20):8977-81.
    View in: PubMed
  152. Chabner BA, Rothenberg ML. Medical oncology in the 1990s. Lancet. 1991 Aug 31; 338(8766):576-7.
    View in: PubMed
  153. Monfardini S, Chabner B. Joint NCI-EORTC consensus meeting on neoplasia in the elderly. San Servolo Island, Venice, 15-16 October 1990. Eur J Cancer. 1991; 27(5):653-4.
    View in: PubMed
  154. Chabner BA, Wilson W. Reversal of multidrug resistance. J Clin Oncol. 1991 Jan; 9(1):4-6.
    View in: PubMed
  155. Grem JL, Chabner BA, Chu E, Johnson P, Yeh GC, Allegra CJ. Antimetabolites. Cancer Chemother Biol Response Modif. 1991; 12:1-25.
    View in: PubMed
  156. Chabner BA, Horwitz SB, Clendennin NJ, Purvis JD. Vinca alkaloids. Cancer Chemother Biol Response Modif. 1991; 12:67-73.
    View in: PubMed
  157. Chabner BA. Salvage therapy for diffuse large-cell lymphoma. Blood. 1990 Oct 1; 76(7):1267-8.
    View in: PubMed
  158. Collins JM, Grieshaber CK, Chabner BA. Pharmacologically guided phase I clinical trials based upon preclinical drug development. J Natl Cancer Inst. 1990 Aug 15; 82(16):1321-6.
    View in: PubMed
  159. Chabner BA. In defense of cell-line screening. J Natl Cancer Inst. 1990 Jul 4; 82(13):1083-5.
    View in: PubMed
  160. Rothenberg M, Chabner BA. Oncology. JAMA. 1990 May 16; 263(19):2667-8.
    View in: PubMed
  161. Allegra CJ, Boarman D, Kovacs JA, Morrison P, Beaver J, Chabner BA, Masur H. Interaction of sulfonamide and sulfone compounds with Toxoplasma gondii dihydropteroate synthase. J Clin Invest. 1990 Feb; 85(2):371-9.
    View in: PubMed
  162. Allegra CJ, Grem JL, Chu E, Johnston P, Yeh GC, Chabner BA. Antimetabolites. Cancer Chemother Biol Response Modif. 1990; 11:1-28.
    View in: PubMed
  163. Chabner BA, Horwitz SB. Plant alkaloids. Cancer Chemother Biol Response Modif. 1990; 11:74-81.
    View in: PubMed
  164. Christian MC, Wittes RE, Leyland-Jones B, McLemore TL, Smith AC, Grieshaber CK, Chabner BA, Boyd MR. 4-Ipomeanol: a novel investigational new drug for lung cancer. J Natl Cancer Inst. 1989 Aug 2; 81(15):1133-43.
    View in: PubMed
  165. Kovacs JA, Allegra CJ, Beaver J, Boarman D, Lewis M, Parrillo JE, Chabner B, Masur H. Characterization of de novo folate synthesis in Pneumocystis carinii and Toxoplasma gondii: potential for screening therapeutic agents. J Infect Dis. 1989 Aug; 160(2):312-20.
    View in: PubMed
  166. Chabner BA, Fojo A. Multidrug resistance: P-glycoprotein and its allies--the elusive foes. J Natl Cancer Inst. 1989 Jun 21; 81(12):910-3.
    View in: PubMed
  167. Chabner BA, Shoemaker D. Drug development for cancer: implications for chemical modifiers. Int J Radiat Oncol Biol Phys. 1989 Apr; 16(4):907-9.
    View in: PubMed
  168. Knight CB, Elwood PC, Chabner BA. Future directions for antifolate drug development. Adv Enzyme Regul. 1989; 29:3-12.
    View in: PubMed
  169. Chabner BA. In celebration of a Nobel Prize. J Natl Cancer Inst. 1988 Dec 7; 80(19):1512-3.
    View in: PubMed
  170. Chabner BA, Browne MJ. Prospects for the drug treatment of cancer. Trans Stud Coll Physicians Phila. 1988 Dec; 10(1-4):103-9.
    View in: PubMed
  171. Vogelzang NJ, Chabner BA, Periman P, Ohrt DK, McCann BC, Burns JM, Bayer R. Reimbursement issues in clinical oncology. Semin Oncol. 1988 Dec; 15(6 Suppl 6):34-43.
    View in: PubMed
  172. Kovacs JA, Allegra CJ, Kennedy S, Swan JC, Drake J, Parrillo JE, Chabner B, Masur H. Efficacy of trimetrexate, a potent lipid-soluble antifolate, in the treatment of rodent Pneumocystis carinii pneumonia. Am J Trop Med Hyg. 1988 Nov; 39(5):491-6.
    View in: PubMed
  173. Glick JH, Chabner BA, Benson JA. Evaluation of clinical competence in medical oncology training programs. J Clin Oncol. 1988 Sep; 6(9):1516-9.
    View in: PubMed
  174. Baram J, Chabner BA, Drake JC, Fitzhugh AL, Sholar PW, Allegra CJ. Identification and biochemical properties of 10-formyldihydrofolate, a novel folate found in methotrexate-treated cells. J Biol Chem. 1988 May 25; 263(15):7105-11.
    View in: PubMed
  175. Chabner BA, Gottesman MM. Meeting highlights: William Guy Forbeck Foundation think tank on "multidrug resistance in cancer chemotherapy". J Natl Cancer Inst. 1988 May 18; 80(6):391-4.
    View in: PubMed
  176. Kovacs JA, Allegra CJ, Swan JC, Drake JC, Parrillo JE, Chabner BA, Masur H. Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate. Antimicrob Agents Chemother. 1988 Apr; 32(4):430-3.
    View in: PubMed
  177. Allegra CJ, Chabner BA, Tuazon CU, Ogata-Arakaki D, Baird B, Drake JC, Masur H. Treatment of Pneumocystis carinii pneumonia with trimetrexate in acquired immunodeficiency syndrome (AIDS). Semin Oncol. 1988 Apr; 15(2 Suppl 2):46-9.
    View in: PubMed
  178. Rogers P, Allegra CJ, Murphy RF, Drake JC, Masur H, Poplack DG, Chabner BA, Parrillo JE, Lane HC, Balis FM. Bioavailability of oral trimetrexate in patients with acquired immunodeficiency syndrome. Antimicrob Agents Chemother. 1988 Mar; 32(3):324-6.
    View in: PubMed
  179. Shiroky J, Allegra C, Inghirami G, Chabner B, Yarboro C, Klippel JH. High dose intravenous methotrexate with leucovorin rescue in rheumatoid arthritis. J Rheumatol. 1988 Feb; 15(2):251-5.
    View in: PubMed
  180. Allegra CJ, Grem JL, Yeh GC, Chabner BA. Antimetabolites. Cancer Chemother Biol Response Modif. 1988; 10:1-22.
    View in: PubMed
  181. Fine RL, Patel J, Chabner BA. Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci U S A. 1988 Jan; 85(2):582-6.
    View in: PubMed
  182. Kao-Shan CS, Fine RL, Whang-Peng J, Lee EC, Chabner BA. Increased fragile sites and sister chromatid exchanges in bone marrow and peripheral blood of young cigarette smokers. Cancer Res. 1987 Dec 1; 47(23):6278-82.
    View in: PubMed
  183. Yeh GC, Occhipinti SJ, Cowan KH, Chabner BA, Myers CE. Adriamycin resistance in human tumor cells associated with marked alteration in the regulation of the hexose monophosphate shunt and its response to oxidant stress. Cancer Res. 1987 Nov 15; 47(22):5994-9.
    View in: PubMed
  184. Allegra CJ, Chabner BA, Tuazon CU, Ogata-Arakaki D, Baird B, Drake JC, Simmons JT, Lack EE, Shelhamer JH, Balis F, et al. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1987 Oct 15; 317(16):978-85.
    View in: PubMed
  185. Drake JC, Allegra CJ, Baram J, Kaufman BT, Chabner BA. Effects on dihydrofolate reductase of methotrexate metabolites and intracellular folates formed following methotrexate exposure of human breast cancer cells. Biochem Pharmacol. 1987 Jul 15; 36(14):2416-8.
    View in: PubMed
  186. Kovacs JA, Allegra CJ, Chabner BA, Swan JC, Drake J, Lunde M, Parrillo JE, Masur H. Potent effect of trimetrexate, a lipid-soluble antifolate, on Toxoplasma gondii. J Infect Dis. 1987 May; 155(5):1027-32.
    View in: PubMed
  187. DeVita VT, Broder S, Fauci AS, Kovacs JA, Chabner BA. Developmental therapeutics and the acquired immunodeficiency syndrome. Ann Intern Med. 1987 Apr; 106(4):568-81.
    View in: PubMed
  188. Fine RL, Koizumi S, Curt GA, Chabner BA. Effect of calcium channel blockers on human CFU-GM with cytotoxic drugs. J Clin Oncol. 1987 Mar; 5(3):489-95.
    View in: PubMed
  189. Allegra CJ, Kovacs JA, Drake JC, Swan JC, Chabner BA, Masur H. Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent. J Exp Med. 1987 Mar 1; 165(3):926-31.
    View in: PubMed
  190. Baram J, Allegra CJ, Fine RL, Chabner BA. Effect of methotrexate on intracellular folate pools in purified myeloid precursor cells from normal human bone marrow. J Clin Invest. 1987 Mar; 79(3):692-7.
    View in: PubMed
  191. Allegra CJ, Kovacs JA, Drake JC, Swan JC, Chabner BA, Masur H. Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate. J Clin Invest. 1987 Feb; 79(2):478-82.
    View in: PubMed
  192. Myers C, Cowan K, Sinha B, Chabner B. The phenomenon of pleiotropic drug resistance. Important Adv Oncol. 1987; 27-38.
    View in: PubMed
  193. Allegra CJ, Baram J, Chabner BA, Yeh GC, Aiba K, Curt GA. Antimetabolites. Cancer Chemother Biol Response Modif. 1987; 9:1-22.
    View in: PubMed
  194. Fitzhugh AL, Chabner BA, Sholar PW, Baram J, Allegra CJ. Antifolate metabolism and sites of action: implications for the design of new antifolates. NCI Monogr. 1987; (5):153-7.
    View in: PubMed
  195. Allegra CJ, Chabner BA, Sholar PW, Bagley C, Drake JC, Lippman ME. Preliminary results of a phase II trial for the treatment of metastatic breast cancer with 5-fluorouracil and leucovorin. NCI Monogr. 1987; (5):199-202.
    View in: PubMed
  196. DeVita VT, Longo DL, Hubbard SM, Young RC, Chabner BA. The lymphomas: biologic implications of therapy and therapeutic implications of the new biology. Monogr Pathol. 1987; (29):249-67.
    View in: PubMed
  197. Fine RL, Chabner BA. Multidrug resistance. Cancer Chemother Biol Response Modif. 1987; 9:81-92.
    View in: PubMed
  198. Allegra CJ, Fine RL, Drake JC, Chabner BA. The effect of methotrexate on intracellular folate pools in human MCF-7 breast cancer cells. Evidence for direct inhibition of purine synthesis. J Biol Chem. 1986 May 15; 261(14):6478-85.
    View in: PubMed
  199. Chabner BA. Karnofsky memorial lecture. The oncologic end game. J Clin Oncol. 1986 May; 4(5):626-38.
    View in: PubMed
  200. Drake JC, Allegra CJ, Chabner BA. A re-evaluation of the competitive protein binding assay for methotrexate binding to dihydrofolate reductase. Biochem Pharmacol. 1986 Apr 1; 35(7):1212-4.
    View in: PubMed
  201. Chabner BA, Reed E. Progress and perspectives of systemic anticancer treatment. Nouv Rev Fr Hematol. 1986; 28(6):333-8.
    View in: PubMed
  202. Collins JM, Zaharko DS, Dedrick RL, Chabner BA. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep. 1986 Jan; 70(1):73-80.
    View in: PubMed
  203. Lippman ME, Chabner BA. National Institutes of Health Consensus Development Conference on Adjuvant Chemotherapy and Endocrine Therapy for Breast Cancer. Editorial overview. NCI Monogr. 1986; (1):5-10.
    View in: PubMed
  204. Curt GA, Jolivet J, Carney DN, Bailey BD, Drake JC, Clendeninn NJ, Chabner BA. Determinants of the sensitivity of human small-cell lung cancer cell lines to methotrexate. J Clin Invest. 1985 Oct; 76(4):1323-9.
    View in: PubMed
  205. Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, Drake JC, Jolivet J. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest. 1985 Sep; 76(3):907-12.
    View in: PubMed
  206. Zimm S, Johnson GE, Chabner BA, Poplack DG. Cellular pharmacokinetics of mercaptopurine in human neoplastic cells and cell lines. Cancer Res. 1985 Sep; 45(9):4156-61.
    View in: PubMed
  207. Allegra CJ, Chabner BA, Drake JC, Lutz R, Rodbard D, Jolivet J. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem. 1985 Aug 15; 260(17):9720-6.
    View in: PubMed
  208. Allegra CJ, Drake JC, Jolivet J, Chabner BA. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci U S A. 1985 Aug; 82(15):4881-5.
    View in: PubMed
  209. Allegra CJ, Drake JC, Bell BA, Curt GA, Chabner BA. Measuring levels of methotrexate. N Engl J Med. 1985 Jul 18; 313(3):184.
    View in: PubMed
  210. Koizumi S, Fine RL, Curt GA, Griffin JD, Chabner BA. Enrichment of myeloid progenitor cells from normal human bone marrow using an immune-rosette technique. Exp Hematol. 1985 Jul; 13(6):560-5.
    View in: PubMed
  211. Drake JC, Allegra CJ, Curt GA, Chabner BA. Competitive protein-binding assay for trimetrexate. Cancer Treat Rep. 1985 Jun; 69(6):641-4.
    View in: PubMed
  212. Chabner BA. The evolution of cancer chemotherapy. Hosp Pract (Off Ed). 1985 Apr 15; 20(4):115-9, 123-7.
    View in: PubMed
  213. Koizumi S, Curt GA, Fine RL, Griffin JD, Chabner BA. Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow. J Clin Invest. 1985 Mar; 75(3):1008-14.
    View in: PubMed
  214. Chabner BA, Fine RL, Allegra CJ, Yeh GW, Curt GA. Cancer chemotherapy. Progress and expectations, 1984. Cancer. 1984 Dec 1; 54(11 Suppl):2599-608.
    View in: PubMed
  215. Chabner BA, Wittes R, Hoth D, Hubbard S. Investigational trials of anticancer drugs: establishing safeguards for experimentation. Public Health Rep. 1984 Jul-Aug; 99(4):355-60.
    View in: PubMed
  216. Chabner BA, Curt GA, Hubbard SM. Surgical oncology research development: the perspective of the National Cancer Institute. Cancer Treat Rep. 1984 Jun; 68(6):825-9.
    View in: PubMed
  217. Curt GA, Jolivet J, Bailey BD, Carney DN, Chabner BA. Synthesis and retention of methotrexate polyglutamates by human small cell lung cancer. Biochem Pharmacol. 1984 May 15; 33(10):1682-5.
    View in: PubMed
  218. Curt GA, Clendeninn NJ, Chabner BA. Drug resistance in cancer. Cancer Treat Rep. 1984 Jan; 68(1):87-99.
    View in: PubMed
  219. Curt GA, Cowan KH, Chabner BA. Gene amplification in drug resistance: of mice and men. J Clin Oncol. 1984 Jan; 2(1):62-4.
    View in: PubMed
  220. Zimm S, Collins JM, O'Neill D, Chabner BA, Poplack DG. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther. 1983 Dec; 34(6):810-7.
    View in: PubMed
  221. Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA. The pharmacology and clinical use of methotrexate. N Engl J Med. 1983 Nov 3; 309(18):1094-104.
    View in: PubMed
  222. Chabner BA, Clendeninn NJ, Curt GA. Symposium on cellular resistance to anticancer drugs. Introduction. Cancer Treat Rep. 1983 Oct; 67(10):855-7.
    View in: PubMed
  223. Jolivet J, Chabner BA. Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase. J Clin Invest. 1983 Sep; 72(3):773-8.
    View in: PubMed
  224. Geffen DB, Gill VJ, Chabner BA. Campylobacter thrombophlebitis. Ann Intern Med. 1983 Jul; 99(1):126.
    View in: PubMed
  225. Doyle LA, Berg C, Bottino G, Chabner B. Erythema and desquamation after high-dose methotrexate. Ann Intern Med. 1983 May; 98(5 Pt 1):611-2.
    View in: PubMed
  226. Zimm S, Collins JM, Riccardi R, O'Neill D, Narang PK, Chabner B, Poplack DG. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med. 1983 Apr 28; 308(17):1005-9.
    View in: PubMed
  227. Fisher RI, DeVita VT, Hubbard SM, Longo DL, Wesley R, Chabner BA, Young RC. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Ann Intern Med. 1983 Mar; 98(3):304-9.
    View in: PubMed
  228. Curt GA, Carney DN, Cowan KH, Jolivet J, Bailey BD, Drake JC, Chien Song KS, Minna JD, Chabner BA. Unstable methotrexate resistance in human small-cell carcinoma associated with double minute chromosomes. N Engl J Med. 1983 Jan 27; 308(4):199-202.
    View in: PubMed
  229. Schilsky RL, Jolivet J, Bailey BD, Chabner BA. Synthesis, binding and intracellular retention of methotrexate polyglutamates by cultured human breast cancer cells. Adv Exp Med Biol. 1983; 163:247-57.
    View in: PubMed
  230. Kerr IG, Jolivet J, Collins JM, Drake JC, Chabner BA. Test dose for predicting high-dose methotrexate infusions. Clin Pharmacol Ther. 1983 Jan; 33(1):44-51.
    View in: PubMed
  231. Ellims PH, Kao AY, Chabner BA. Kinetic behaviour and allosteric regulation of human deoxycytidylate deaminase derived from leukemic cells. Mol Cell Biochem. 1983; 57(2):185-90.
    View in: PubMed
  232. Anderson T, Chabner BA, Young RC, Berard CW, Garvin AJ, Simon RM, DeVita VT. Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute. Cancer. 1982 Dec 15; 50(12):2699-707.
    View in: PubMed
  233. Jolivet J, Schilsky RL, Bailey BD, Chabner BA. The synthesis and retention of methotrexate polyglutamates in cultured human breast cancer cells. Ann N Y Acad Sci. 1982 Dec 10; 397:184-92.
    View in: PubMed
  234. Jolivet J, Schilsky RL, Bailey BD, Drake JC, Chabner BA. Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells. J Clin Invest. 1982 Aug; 70(2):351-60.
    View in: PubMed
  235. Tamarkin L, Danforth D, Lichter A, DeMoss E, Cohen M, Chabner B, Lippman M. Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. Science. 1982 May 28; 216(4549):1003-5.
    View in: PubMed
  236. Riccardi R, Chabner B, Glaubiger DL, Wood J, Poplack DG. Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1982 May; 42(5):1736-9.
    View in: PubMed
  237. Hubbard SM, Chabner BA, DeVita VT, Simon R, Berard CW, Jones RB, Garvin AJ, Canellos GP, Osborne CK, Young RC. Histologic progression in non-Hodgkin's lymphoma. Blood. 1982 Feb; 59(2):258-64.
    View in: PubMed
  238. Erlichman C, Donehower RC, Speyer JL, Klecker R, Chabner BA. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection. J Natl Cancer Inst. 1982 Feb; 68(2):227-31.
    View in: PubMed
  239. Liang CM, Donehower RC, Chabner BA. Biochemical interactions between N-(phosphonacetyl)-L-aspartate and 5-fluorouracil. Mol Pharmacol. 1982 Jan; 21(1):224-30.
    View in: PubMed
  240. Tamarkin L, Cohen M, Roselle D, Reichert C, Lippman M, Chabner B. Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in the rat. Cancer Res. 1981 Nov; 41(11 Pt 1):4432-6.
    View in: PubMed
  241. Ellims PH, Kao AY, Chabner BA. Deoxycytidylate deaminase. Purification and some properties of the enzyme isolated from human spleen. J Biol Chem. 1981 Jun 25; 256(12):6335-40.
    View in: PubMed
  242. Schilsky RL, Bailey BD, Chabner BA. Characteristics of membrane transport of methotrexate by cultured human breast cancer cells. Biochem Pharmacol. 1981 Jun 15; 30(12):1537-42.
    View in: PubMed
  243. Hande KR, Hixson CV, Chabner BA. Postchemotherapy purine excretion in lymphoma patients receiving allopurinol. Cancer Res. 1981 Jun; 41(6):2273-9.
    View in: PubMed
  244. Chabner BA, Rustum YM, Slocum HK. The role of target determinants in antineoplastic therapy. Cancer Treat Rep. 1981; 65 Suppl 3:27-31.
    View in: PubMed
  245. Chabner BA, Donehower RC, Schilsky RL. Clinical pharmacology of methotrexate. Cancer Treat Rep. 1981; 65 Suppl 1:51-4.
    View in: PubMed
  246. Chabner BA, Fisher RI, Young RC, DeVita VT. Staging of non-Hodgkin's lymphoma. Semin Oncol. 1980 Sep; 7(3):285-91.
    View in: PubMed
  247. Erlichman C, Strong JM, Chabner BA. Application of a simple competitive protein-binding assay technique to the pharmacokinetics of N-(phosphonacetyl)-L-aspartate in humans. Cancer Res. 1980 Jun; 40(6):1902-6.
    View in: PubMed
  248. Schilsky RL, Bailey BD, Chabner BA. Methotrexate polyglutamate synthesis by cultured human breast cancer cells. Proc Natl Acad Sci U S A. 1980 May; 77(5):2919-22.
    View in: PubMed
  249. Donehower RC, Allegra JC, Lippman ME, Chabner BA. Combined effects of methotrexate and 5-fluoropyrimidine on human breast cancer cells in serum-free culture. Eur J Cancer. 1980 May; 16(5):655-61.
    View in: PubMed
  250. Drake JC, Hande KR, Fuller RW, Chabner BA. Cytidine and deoxycytidylate deaminase inhibition by uridine analogs. Biochem Pharmacol. 1980 Mar 1; 29(5):807-11.
    View in: PubMed
  251. Liang CM, Liu YP, Chabner BA. Modes of action of hypoxanthine, inosine and inosine 5'-monophosphate on cyclic nucleotide phosphodiesterase from bovine brain. Biochem Pharmacol. 1980 Feb; 29(3):277-82.
    View in: PubMed
  252. Hande KR, Chabner BA. A competitive protein binding assay for allopurinol and oxipurinol. Anal Biochem. 1980 Jan 1; 101(1):26-33.
    View in: PubMed
  253. Erlichman C, Donehower RC, Chabner BA. The practical benefits of pharmacokinetics in the use of antineoplastic agents. Cancer Chemother Pharmacol. 1980; 4(3):139-45.
    View in: PubMed
  254. Liang CM, Liu YP, Chabner BA. Isolation and identification of a small molecular weight inhibitor of cyclic nucleotide phosphodiesterase from bovine brain. Biochim Biophys Acta. 1979 Nov 9; 571(1):63-9.
    View in: PubMed
  255. Come SE, Chabner BA. Staging in non-Hodgkin's lymphoma: approach, results and relationship to histopathology. Clin Haematol. 1979 Oct; 8(3):645-56.
    View in: PubMed
  256. Erlichman C, Strong JM, Wiernik PH, McAvoy LM, Cohen MH, Levine AS, Hubbard SM, Chabner BA. Phase I trial of N-(phosphonacetyl)-L-aspartate. Cancer Res. 1979 Oct; 39(10):3992-5.
    View in: PubMed
  257. Donehower RC, Myers CE, Chabner BA. New developments on the mechanisms of action of antineoplastic drugs. Life Sci. 1979 Jul 2; 25(1):1-14.
    View in: PubMed
  258. Donehower RC, Hande KR, Drake JC, Chabner BA. Presence of 2,4-diamino-N10-methylpteroic acid after high-dose methotrexate. Clin Pharmacol Ther. 1979 Jul; 26(1):63-72.
    View in: PubMed
  259. Murinson DS, Anderson T, Schwartz HS, Myers CE, Chabner BA. Competitive binding radioassay for 5-fluorodeoxyuridine 5'-monophosphate in tissues. Cancer Res. 1979 Jul; 39(7 Pt 1):2471-5.
    View in: PubMed
  260. Rosenburg SA, Chabner BA, Young RC, Seipp CA, Levine AS, Costa J, Hanson TA, Head GC, Simon RM. Treatment of osteogenic sarcoma. I. Effect of adjuvant high-dose methotrexate after amputation. Cancer Treat Rep. 1979 May; 63(5):739-51.
    View in: PubMed
  261. Fisher RI, Chabner BA, Myers CE. Phase II study of high-dose methotrexate in patients with advanced malignant melanoma. Cancer Treat Rep. 1979 Jan; 63(1):147-8.
    View in: PubMed
  262. Chabner BA. Nodular Non-Hodgkin's lymphoma: the case for watchful waiting. Ann Intern Med. 1979 Jan; 90(1):115-7.
    View in: PubMed
  263. Chabner BA, Hande KR, Drake JC. Ara-C metabolism: implications for drug resistance and drug interactions. Bull Cancer. 1979; 66(1):89-92.
    View in: PubMed
  264. Locker GY, Doroshow JH, Zwelling LA, Chabner BA. The clinical features of hepatic angiosarcoma: a report of four cases and a review of the English literature. Medicine (Baltimore). 1979 Jan; 58(1):48-64.
    View in: PubMed
  265. Jones RA, Buckpitt AR, Londer HH, Myers CE, Chabner BA, Boyd MR. Potential clinical applications of a new method for quantitation of plasma levels of 5-fluorouracil and 5-fluorodeoxyuridine. Bull Cancer. 1979; 66(1):75-8.
    View in: PubMed
  266. Hande KR, Chretien PB, Elias EG, Goldberg NH, Brooks AE, Chabner BA. Thirty-six-hour preoperative high-dose methotrexate infusion in patients with squamous carcinoma of the head and neck. Med Pediatr Oncol. 1979; 6(1):39-45.
    View in: PubMed
  267. Young RC, Chabner BA, Hubbard SP, Fisher RI, Bender RA, Anderson T, Simon RM, Canellos GP, DeVita VT. Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med. 1978 Dec 7; 299(23):1261-6.
    View in: PubMed
  268. Cohen M, Lippman M, Chabner B. Pineal gland and breast cancer. Lancet. 1978 Dec 23-30; 2(8104-5):1381-2.
    View in: PubMed
  269. Johnson BL, Fisher RI, Bender RA, DeVita VT, Chabner BA, Young RC. Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma. Cancer. 1978 Nov; 42(5):2157-61.
    View in: PubMed
  270. Cohen M, Lippman M, Chabner B. Role of pineal gland in aetiology and treatment of breast cancer. Lancet. 1978 Oct 14; 2(8094):814-6.
    View in: PubMed
  271. Cohen M, Bender RA, Donehower R, Myers CE, Chabner BA. Reversibility of high-affinity binding of methotrexate in L1210 murine leukemia cells. Cancer Res. 1978 Sep; 38(9):2866-70.
    View in: PubMed
  272. Greene MH, Macher AM, Hernandez AD, Tomecki KJ, Chabner B. Disseminated cryptococcosis presenting as palpable purpura. Arch Intern Med. 1978 Sep; 138(9):1412-3.
    View in: PubMed
  273. Cohen M, Roselle D, Chabner B, Schmidt TJ, Lippman M. Evidence for a cytoplasmic melatonin receptor. Nature. 1978 Aug 31; 274(5674):894-5.
    View in: PubMed
  274. Young RC, Canellos GP, Chabner BA, Hubbard SM, DeVita VT. Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy. Cancer. 1978 Aug; 42(2 Suppl):1001-7.
    View in: PubMed
  275. Chabner BA, Johnson RE, Young RC, Canellos GP, Hubbard SP, Johnson SK, DeVita VT. Sequential nonsurgical and surgical staging of non-Hodgkin's lymphoma. Cancer. 1978 Aug; 42(2 Suppl):922-5.
    View in: PubMed
  276. Bender RA, Zwelling LA, Doroshow JH, Locker GY, Hande KR, Murinson DS, Cohen M, Myers CE, Chabner BA. Antineoplastic drugs: clinical pharmacology and therapeutic use. Drugs. 1978 Jul; 16(1):46-87.
    View in: PubMed
  277. Rosenberg SA, Kent H, Costa J, Webber BL, Young R, Chabner B, Baker AR, Brennan MF, Chretien PB, Cohen MH, deMoss EV, Sears HF, Seipp C, Simon R. Prospective randomized evaluation of the role of limb-sparing surgery, radiation therapy, and adjuvant chemoimmunotherapy in the treatment of adult soft-tissue sarcomas. Surgery. 1978 Jul; 84(1):62-9.
    View in: PubMed
  278. Chabner BA, Cohen M, Lippman M. Adjuvant therapy of breast cancer: accomplishments and future course. JAMA. 1978 Jun 2; 239(22):2373-4.
    View in: PubMed
  279. Hande K, Reed E, Chabner B. Allopurinol kinetics. Clin Pharmacol Ther. 1978 May; 23(5):598-605.
    View in: PubMed
  280. Hande KR, Fisher RI, DeVita VT, Chabner BA, Young RC. Diffuse histiocytic lymphoma involving the gastrointestinal tract. Cancer. 1978 May; 41(5):1984-9.
    View in: PubMed
  281. Chabner BA, Levine AS, Johnson BL, Young RC. Initial clinical trials of maytansine, an antitumor plant alkaloid. Cancer Treat Rep. 1978 Mar; 62(3):429-33.
    View in: PubMed
  282. Johnson RE, Canellos GP, Young RC, Chabner BA, DeVita VT. Chemotherapy (cyclophosphamide, vincristine, and prednisone) versus radiotherapy (total body irradiation) for stage III-IV poorly differentiated lymphocytic lymphoma. Cancer Treat Rep. 1978 Mar; 62(3):321-5.
    View in: PubMed
  283. Hande KR, Chabner BA. Pyrimidine nucleoside monophosphate kinase from human leukemic blast cells. Cancer Res. 1978 Mar; 38(3):579-85.
    View in: PubMed
  284. Stoller RG, Myers CE, Chabner BA. Analysis of cytidine deaminase and tetrahydrouridine interaction by use of ligand techniques. Biochem Pharmacol. 1978 Jan 1; 27(1):53-9.
    View in: PubMed
  285. Chabner BA, Stoller RG, Hande K, Jacobs S, Young RC. Methotrexate disposition in humans: case studies in ovarian cancer and following high-dose infusion. Drug Metab Rev. 1978; 8(1):107-17.
    View in: PubMed
  286. Liu YP, Wong VG, Chabner BA. Cyclic nucleotide phosphodiesterase and protein activator in human cancer cell lines and Brown-Pearce carcinoma. J Natl Cancer Inst. 1977 Dec; 59(6):1605-9.
    View in: PubMed
  287. Hande KR, Balow JE, Drake JC, Rosenberg SA, Chabner BA. Methotrexate and hemodialysis. Ann Intern Med. 1977 Oct; 87(4):495-6.
    View in: PubMed
  288. Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med. 1977 Sep 22; 297(12):630-4.
    View in: PubMed
  289. Chabner BA, Johnson RE, DeVita VT, Canellos GP, Hubbard SP, Johnson SK, Young RC. Sequential staging in non-Hodgkin's lymphoma. Cancer Treat Rep. 1977 Sep; 61(6):993-7.
    View in: PubMed
  290. Anderson T, Bender RA, Fisher RI, DeVita VT, Chabner BA, Berard CW, Norton L, Young RC. Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup. Cancer Treat Rep. 1977 Sep; 61(6):1057-66.
    View in: PubMed
  291. Young RC, Johnson RE, Canellos GP, Chabner BA, Brereton HD, Berard CW, DeVita VT. Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination. Cancer Treat Rep. 1977 Sep; 61(6):1153-9.
    View in: PubMed
  292. Anderson T, Bender RA, Rosenoff SH, Brereton HD, Chabner BA, DeVita VT, Hubbard SP, Young RC. Peritoneoscopy: a technique to evaluate therapeutic efficacy in non-Hodgkin's lymphoma patients. Cancer Treat Rep. 1977 Sep; 61(6):1017-22.
    View in: PubMed
  293. Chabner BA. Second neoplasm--a complication of cancer chemotherapy. N Engl J Med. 1977 Jul 28; 297(4):213-5.
    View in: PubMed
  294. Jacobs SA, Stoller RG, Chabner BA, Johns DG. Dose-dependent metabolism of methotrexate in man and rhesus monkeys. Cancer Treat Rep. 1977 Jul; 61(4):651-6.
    View in: PubMed
  295. Pinedo HM, Chabner BA. Role of drug concentration, duration of exposure, and endogenous metabolites in determining methotrexate cytotoxicity. Cancer Treat Rep. 1977 Jul; 61(4):709-15.
    View in: PubMed
  296. Reimer RR, Chabner BA, Young RC, Reddick R, Johnson RE. Lymphoma presenting in bone: results of histopathology, staging, and therapy. Ann Intern Med. 1977 Jul; 87(1):50-5.
    View in: PubMed
  297. Chabner BA, Myers CE, Oliverio VT. Clinical pharmacology of anticancer drugs. Semin Oncol. 1977 Jun; 4(2):165-91.
    View in: PubMed
  298. Ross WE, Chabner BA. Allergic reaction to cyclophosphamide in a mechlorethamine-sensitive patient. Cancer Treat Rep. 1977 May-Jun; 61(3):495-6.
    View in: PubMed
  299. Pinedo HM, Zaharko DS, Bull J, Chabner BA. The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion. Cancer Res. 1977 Feb; 37(2):445-50.
    View in: PubMed
  300. Rosental S, Balasa RW, Chabner B. Metastatic mediastinal carcinoid treated with chemotherapy. Cancer Treat Rep. 1977 Jan-Feb; 61(1):108.
    View in: PubMed
  301. Coller BS, Chabner BA, Gralnick HR. Frequencies and patterns of bone marrow involvement in non-Hodgkin lymphomas: observations on the value of bilateral biopsies. Am J Hematol. 1977; 3:105-19.
    View in: PubMed
  302. Drake JC, Stoller RG, Chabner BA. Characteristics of the enzyme uridine-cytidine kinase isolated from a cultured human cell line. Biochem Pharmacol. 1977 Jan 1; 26(1):64-6.
    View in: PubMed
  303. Pinedo HM, Zaharko DS, Bull JM, Chabner BA. The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides. Cancer Res. 1976 Dec; 36(12):4418-24.
    View in: PubMed
  304. Schein PS, DeVita VT, Hubbard S, Chabner BA, Canellos GP, Berard C, Young RC. Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann Intern Med. 1976 Oct; 85(4):417-22.
    View in: PubMed
  305. Hande KR, Witebsky FG, Brown MS, Schulman CB, Anderson SE, Levine AS, MacLowery JD, Chabner BA. Sepsis with a new species of Corynebacterium. Ann Intern Med. 1976 Oct; 85(4):423-6.
    View in: PubMed
  306. Myers CE, Diasio R, Eliot HM, Chabner BA. Pharmacokinetics of the fluoropyrimidines: implications for their clinical use. Cancer Treat Rev. 1976 Sep; 3(3):175-83.
    View in: PubMed
  307. Pinedo HM, Chabner BA, Zaharko DS, Bull JM. Evidence for early recruitment of granulocyte precursors during high-dose methotrexate infusions in mice. Blood. 1976 Aug; 48(2):301-7.
    View in: PubMed
  308. Chabner BA, Johnson RE, Young RC, Canellos GP, Hubbard SP, Johnson SK, DeVita VT. Sequential nonsurgical and surgical staging of non-Hodgkin's lymphoma. Ann Intern Med. 1976 Aug; 85(2):149-54.
    View in: PubMed
  309. Canellos GP, DeVita VT, Whang-Peng J, Chabner BA, Schein PS, Young RC. Chemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy. Blood. 1976 Jun; 47(6):1003-9.
    View in: PubMed
  310. Myers CE, Young RC, Chabner BA. Kinetic alterations induced by 5-fluorouracil in bone marrow, intestinal mucosa, and tumor. Cancer Res. 1976 May; 36(5):1653-8.
    View in: PubMed
  311. Myers CE, Eliot HM, Chabner BA. Competitive dihydrofolate reductase binding assay of triazinate (NSC-139105), methasquin (NSC-122870), and aminopterin (NSC739). Cancer Treat Rep. 1976 May; 60(5):615-6.
    View in: PubMed
  312. Levenson SM, Warren RD, Richman SD, Johnston GS, Chabner BA. Abnormal pulmonary gallium accumulation in P. carinii pneumonia. Radiology. 1976 May; 119(2):395-8.
    View in: PubMed
  313. Canellos GP, DeVita VT, Gold GL, Chabner BA, Schein PS, Young RC. Combination chemotherapy for advanced breast cancer: response and effect on survival. Ann Intern Med. 1976 Apr; 84(4):389-92.
    View in: PubMed
  314. Jacobs SA, Stoller RG, Chabner BA, Johns DG. 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. J Clin Invest. 1976 Feb; 57(2):534-8.
    View in: PubMed
  315. Lotz MJ, Chabner B, DeVita VT, Johnson RE, Berard CW. Pathological staging of 100 consecutive untreated patients with non-Hodgkin's lymphomas: extramedullary sites of disease. Cancer. 1976 Jan; 37(1):266-70.
    View in: PubMed
  316. Myers CE, Young RC, Chabner BA. Biochemical determinants of 5-fluorouracil response in vivo. The role of deoxyuridylate pool expansion. J Clin Invest. 1975 Nov; 56(5):1231-8.
    View in: PubMed
  317. Coleman CN, Stoller RG, Drake JC, Chabner BA. Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes. Blood. 1975 Nov; 46(5):791-803.
    View in: PubMed
  318. Rosenoff SH, Young RC, Chabner B, Hubbard S, De Vita VT, Schein PS. Use of peritoneoscopy for initial staging and posttherapy evaluation of patients with ovarian carcinoma. Natl Cancer Inst Monogr. 1975 Oct; 42:81-6.
    View in: PubMed
  319. Young RC, Chabner BA, Hubbard SP, Canellos GP, DeVita VT. Preliminary Results of trials of chemotherapy in advanced ovarian carcinoma. Natl Cancer Inst Monogr. 1975 Oct; 42:145-8.
    View in: PubMed
  320. Stoller RG, Coleman CN, Chang P, Hande KR, Chabner BA. Biochemical pharmacology of cytidine analog metabolism in human leukemic cells. Bibl Haematol. 1975 Oct; (43):531-3.
    View in: PubMed
  321. Hubbard SP, Chabner BA, Canellos GP, Young RC, DeVita VT. High dose intravenous bleomycin in the treatment of advanced lymphomas. Eur J Cancer. 1975 Sep; 11(9):623-6.
    View in: PubMed
  322. Myers CE, Lippman ME, Elliot HM, Chabner BA. Competitive protein binding assay for methotrexate. Proc Natl Acad Sci U S A. 1975 Sep; 72(9):3683-6.
    View in: PubMed
  323. Coleman CN, Johns DG, Chabner BA. Studies on mechanisms of resistance to cytosine arabinoside: problems in the determination of related enzyme activities in leukemic cells. Ann N Y Acad Sci. 1975 Aug 8; 255:247-51.
    View in: PubMed
  324. Rosenoff SH, Young RC, Anderson T, Bagley C, Chabner B, Schein PS, Hubbard S, DeVita VT. Peritoneoscopy: a valuable staging tool in ovarian carcinoma. Ann Intern Med. 1975 Jul; 83(1):37-41.
    View in: PubMed
  325. Chabner BA, Myers CE, Coleman CN, Johns DG. The clinical pharmacology of antineoplastic agents (second of two parts). N Engl J Med. 1975 May 29; 292(22):1159-68.
    View in: PubMed
  326. Chabner BA, Myers CE, Coleman CN, Johns DG. The clinical pharmacology of antineoplastic agents (first of two parts). N Engl J Med. 1975 May 22; 292(21):1107-13.
    View in: PubMed
  327. Jacobs SA, Adamson RH, Chabner BA, Derr CJ, Johns DC. Stoichiometric inhibition of mammalian dihydrofolate reductase by the gamma-glutamyl metabolite of methotrexiate, 4-amino-4-deoxy-N-10-methylpteroylglutamyl-gamma-glutamate. Biochem Biophys Res Commun. 1975 Apr 7; 63(3):692-8.
    View in: PubMed
  328. Chabner BA, Johnson RE, Chretien PB, Schein PS, Young RC, Canellos CP, Hubbard SH, Anderson T, Rosenoff SH, DeVita VT. Percutaneous liver biopsy, peritoneoscopy and laparotomy: an assessment of relative merits in the lymphomata. Br J Cancer Suppl. 1975 Mar; 2:242-7.
    View in: PubMed
  329. Schein PS, Chabner BA, Canellos GP, Young RD, Berard C, DeVita VT. Results of combination chemotherapy of non-Hodgkin's lymphoma. Br J Cancer Suppl. 1975 Mar; 2:465-73.
    View in: PubMed
  330. Canellos GP, DeVita VT, Young RC, Chabner BA, Schein PS, Johnson RE. Therapy of advanced lymphocytic lymphoma a preliminary report of a randomized trial between combination chemotherapy (CVP) and intensive radiotherapy. Br J Cancer Suppl. 1975 Mar; 2:474-80.
    View in: PubMed
  331. Johnson RE, DeVita VT, Kun LE, Chabner BR, Chretien PB, Berard CW, Johnson SK. Patterns of involvement with malignant lymphoma and implications for treatment decision making. Br J Cancer Suppl. 1975 Mar; 2:237-41.
    View in: PubMed
  332. Jacobs SA, Bleyer WA, Chabner BA, Johns DG. Letter: Altered plasma pharmacokinetics of methotrexate administered intrathecally. Lancet. 1975 Feb 22; 1(7904):465-6.
    View in: PubMed
  333. Schein PS, Chabner BA, Canellos GP, Young RC, DeVita VT. Non-Hodgkin's lymphoma: patterns of relapse from complete remission after combination chemotherapy. Cancer. 1975 Feb; 35(2):354-7.
    View in: PubMed
  334. DeVita VT, Canellos GP, Chabner B, Schein P, Hubbard SP, Young RC. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet. 1975 Feb 1; 1(7901):248-50.
    View in: PubMed
  335. Canellos GP, DeVita VT, Gold GL, Chabner BA, Schein PS, Young RC. Letter: Combination chemotherapy for breast cancer. Br Med J. 1975 Jan 4; 1(5948):37.
    View in: PubMed
  336. Young RC, Canellos GP, Chabner BA, Schein PS, Hubbard SP, DeVita VT. Chemotherapy of advanced ovarian carcinoma: a prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide. Gynecol Oncol. 1974 Dec; 2(4):489-97.
    View in: PubMed
  337. Myers CE, Young RC, Johns DG, Chabner BA. Assay of 5-fluorodeoxyuridine 5'-monophosphate deoxyuridine 5'-monophosphate pools following 5-fluorouracil. Cancer Res. 1974 Oct; 34(10):2682-8.
    View in: PubMed
  338. Myers CE, Chabner BA, De Vita VT, Gralnick HR. Bone marrow involvement in Hodgkin's disease: pathology and response to MOPP chemotherapy. Blood. 1974 Aug; 44(2):197-204.
    View in: PubMed
  339. Rosenoff SH, Wolf ML, Chabner BA. Pseudomonas blepharoconjunctivitis: a complication of combination chemotherapy. Arch Ophthalmol. 1974 Jun; 91(6):490-1.
    View in: PubMed
  340. Young RC, Canellos GP, Chabner BA, Schein PS, Brereton HD, DeVita VT. Treatment of malignant melanoma with methyl CCNU. Clin Pharmacol Ther. 1974 Jun; 15(6):617-22.
    View in: PubMed
  341. Evans WH, Wolf MM, Chabner BA. Concentration of immature and mature granulocytes from normal human bone marrow. Proc Soc Exp Biol Med. 1974 Jun; 146(2):526-9.
    View in: PubMed
  342. Chabner BA, Johns DG, Coleman CN, Drake JC, Evans WH. Purification and properties of cytidine deaminase from normal and leukemic granulocytes. J Clin Invest. 1974 Mar; 53(3):922-31.
    View in: PubMed
  343. Canellos GP, Devita VT, Gold GL, Chabner BA, Schein PS, Young RC. Cyclical combination chemotherapy for advanced breast carcinoma. Br Med J. 1974 Feb 9; 1(5901):218-20.
    View in: PubMed
  344. Schein PS, Chabner BA, Canellos GP, Young RC, Berard C, DeVita VT. Potential for prolonged disease-free survival following combination chemotherapy of non-Hodgkin's lymphoma. Blood. 1974 Feb; 43(2):181-9.
    View in: PubMed
  345. Chabner BA, Drake JC, Johns DG. Deamination of 5-azacytidine by a human leukemia cell cytidine deaminase. Biochem Pharmacol. 1973 Nov 1; 22(21):2763-5.
    View in: PubMed
  346. Bleyer WA, Drake JC, Chabner BA. Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med. 1973 Oct 11; 289(15):770-3.
    View in: PubMed
  347. Johns DG, Farquhar D, Chabner BA, Wolpert MK, Adamson RH. Antineoplastic activity of lipid-soluble dialkyl esters of methotrexate. Experientia. 1973 Sep 15; 29(9):1104-5.
    View in: PubMed
  348. Chabner BA, Sponzo R, Hubbard S, Canellos GP, Young RC, Schein PS, Devita VT. High-dose intermittent intravenous infusion of procarbazine (NSC-77213). Cancer Chemother Rep. 1973 Sep-Oct; 57(3):361-3.
    View in: PubMed
  349. Chabner BA, Young RC. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest. 1973 Aug; 52(8):1804-11.
    View in: PubMed
  350. Young RC, Canellos GP, Chabner BA, Schein PS, DeVita VT. Maintenance chemotherapy for advanced Hodgkin's disease in remission. Lancet. 1973 Jun 16; 1(7816):1339-43.
    View in: PubMed
  351. Bagley CM, Young RC, Schein PS, Chabner BA, DeVita VT. Ovarian carcinoma metastatic to the diaphragm--frequently undiagnosed at laparotomy. A preliminary report. Am J Obstet Gynecol. 1973 Jun 1; 116(3):397-400.
    View in: PubMed
  352. Young RC, Walker MD, Canellos GP, Schein PS, Chabner BA, DeVita VT. Initial clinical trials with methyl-CCNU 1-(2-chlorethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (MeCCNU). Cancer. 1973 May; 31(5):1164-9.
    View in: PubMed
  353. Johns DG, Farquhar D, Wolpert MK, Chabner BA, Loo TL. Dialkyl esters of methotrexate and 3',5'-dichloromethotrexate: synthesis and interaction with aldehyde oxidase and dihydrofolate reductase. Drug Metab Dispos. 1973 May-Jun; 1(3):580-9.
    View in: PubMed
  354. Chabner BA, Johns DG, Bertino JR. Enzymatic cleavage of methotrexate provides a method for prevention of drug toxicity. Nature. 1972 Oct 13; 239(5372):395-7.
    View in: PubMed
  355. Chabner BA, Chello PL, Bertino JR. Antitumor activity of a folate-cleaving enzyme, carboxypeptidase G 1 . Cancer Res. 1972 Oct; 32(10):2114-9.
    View in: PubMed
  356. Chabner BA, Canellos GP, Olweny CL, DeVita VT. Late recurrence of testicular tumor. N Engl J Med. 1972 Aug 24; 287(8):413.
    View in: PubMed
  357. Chabner BA, Bertino JR. Activation and inhibition of carboxypeptidase G 1 by divalent cations. Biochim Biophys Acta. 1972 Jul 13; 276(1):234-40.
    View in: PubMed
  358. Chabner BA, Brill SJ, Felig P. [Hyperglycemia and insulin resistance during glucagon infusion]. Conn Med. 1972 Apr; 36(4):199-200.
    View in: PubMed
  359. De Vita VT, Canellos GP, Schein PJ, Chabner BA, Bagley CM, Young RC. Proceedings: Malignant lymphoma: treatment with combination chemotherapy. Proc Natl Cancer Conf. 1972; 7:379-90.
    View in: PubMed
  360. Canellos GP, De Vita VT, Schein P, Chabner B, Young RC. Proceedings: The chronic leukemias: current therapeutic concepts. Proc Natl Cancer Conf. 1972; 7:351-7.
    View in: PubMed
  361. McCullough JL, Chabner BA, Bertino JR. Purification and properties of carboxypeptidase G 1 . J Biol Chem. 1971 Dec 10; 246(23):7207-13.
    View in: PubMed
  362. Bertino JR, Levitt M, McCullough JL, Chabner B. New approaches to chemotherapy with folate antagonists: use of leucovorin "rescue" and enzymic folate depletion. Ann N Y Acad Sci. 1971 Nov 30; 186:486-95.
    View in: PubMed
  363. DeVita VT, Chabner BA, Livingston DM, Oliverio VT. Anergy and tryptophan metabolism in Hodgkin's disease. Am J Clin Nutr. 1971 Jul; 24(7):835-40.
    View in: PubMed
  364. Chabner BA, DeVita VT, Livingston DM, Oliverio VT. Abnormalities of tryptophan metabolism and plasma pyridoxal phosphate in Hodgkin's disease. N Engl J Med. 1970 Apr 9; 282(15):838-43.
    View in: PubMed
  365. Chabner B, Livingston D. A simple enzymic assay for pyridoxal phosphate. Anal Biochem. 1970 Apr; 34(2):413-23.
    View in: PubMed
  366. Chabner BA, Stein JA, Tschudy DP. Effect on dietary pyridoxine deficiency on experimental porphyria. Metabolism. 1970 Mar; 19(3):189-91.
    View in: PubMed
  367. Chabner BA, DeVita VT, Considine N, Oliverio VT. Plasma pyridoxal phosphate depletion by the carcinostatic procarbazine. Proc Soc Exp Biol Med. 1969 Dec; 132(3):1119-22.
    View in: PubMed
  368. Chabner BA, Haskell CM, Canellos GP. Destructive bone lesions in chronic granulocytic leukemia. Medicine (Baltimore). 1969 Sep; 48(5):401-10.
    View in: PubMed
  369. Fraumeni JF, Chabner BA, Li FP, Carbone PP. Myotonic dystrophy and leukemia. JAMA. 1969 Apr 28; 208(4):696.
    View in: PubMed
  370. Chabner BA, Easton J, DeVita VT. Shaking chills related to occult lymphoma. Report of a case. Med Ann Dist Columbia. 1969 Jan; 38(1):27-8.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Chabner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (998) concept(s)
_
Co-Authors
See all (62) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_